Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05493488
Other study ID # CT-210
Secondary ID
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date September 8, 2022
Est. completion date December 31, 2023

Study information

Verified date September 2022
Source DermBiont, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a randomized, observer blinded, Aqueous Gel-controlled trial examining the effect of daily application for approximately 6-8 days of DBI-001 Gel, DBI-002 Gel, and Aqueous Gel on the subjects with interdigital tinea pedis based on Whole Genome Sequencing (WGS) and Quantitative Polymerase Chain Reaction (qPCR), and comparison between Quantitative Polymerase Chain Reaction (qPCR) and Potassium Hydroxide (KOH) for the presence of Trichophyton rubrum (T.rubrum) as well as signs and symptoms and local tolerability and toxicity on treated sites in subjects.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 24
Est. completion date December 31, 2023
Est. primary completion date December 31, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: 1. Ability to understand, agree to, and sign the study Informed Consent 2. A signed Health Information Portability and Accountability Act (HIPAA) authorization form which permits the use and disclosure of the subject's individually identifiable health information. 3. Male or Female Subjects of any race 18-65 years of age. 4. Subjects with a clinical diagnosis of interdigital T. pedis. 5. Investigator confirmed diagnosis by a positive T. rubrum potassium hydroxide (KOH) wet mount at Screening at the investigative site. 6. A quantifiable level of T. rubrum based on Sponsor laboratory qPCR from the sample obtained at the Screening visit. 7. The sum of the clinical signs and symptoms scores of at least one web space (Target web space) is at least 4 using the Grading of Signs and Symptoms of T. pedis including a minimum score of 2 for erythema AND a minimum score of 2 for either scaling/fissures or pruritus/burning (on a scale of 0-3, where 2 indicates moderate severity). 8. Target web space(s) should have an adequate amount of leading-edge scale to provide enough scale sampling for KOH. Exclusion Criteria: 1. Women who are pregnant, planning a pregnancy, breastfeeding or have a positive pregnancy test at screening. 2. Any dermatological conditions that could interfere with clinical evaluations 3. The clinical diagnosis of moccasin T. pedis. 4. Subjects with gram negative interdigital tinea pedis based on a clinical diagnosis: Gram-negative athlete's foot - the interspace is foul smelling, whitish, painful, strongly macerated, and hyperkeratotic with erosions, exudation, and intense inflammation and often disabling. 5. Any underlying disease(s) or other dermatological condition that requires the use of interfering topical or systemic therapy. 6. Subjects with concurrent use of any of the following topical preparations who have not completed the specified washout period(s) for the following topical medications applied to the foot at the time of the Screening visit: 1. Washout of 1 week prior to the screening visit for topical astringents and abrasives (e.g., Burrow's solution), Vicks VapoRub, tea tree oil) 2. Washout of 2 weeks prior to the screening visit for topical antibiotics and antifungal on the feet (e.g., Neomycin, Miconazole, Clotrimazole, Terbinafine) 3. Washout of 4 weeks prior to the screening visit for the topical Anti-inflammatories, corticosteroids, topical immunomodulators on the feet (e.g., Pimecrolimus, Tacrolimus) 7. Subjects with concurrent use of any of the following systemic medications who have not completed the specified washout period(s) for the following systemic medications at the time of the Screening visit: 1. Washout of 4 weeks prior to the screening visit for the systemic corticosteroids (including intramuscular injections) (e.g., Triamcinolone acetonide) 2. Washout of 4 weeks prior to the screening visit for the systemic antibiotics (e.g., Tetracycline, Cephalosporins, etc.) and/or Antifungal agents (e.g., Fluconazole, Itraconazole, Terbinafine, etc.) 3. Washout of 4 weeks prior to the screening visit for the systemic immunomodulators (e.g., Cyclophosphamide, Azathioprine, Biologicals-Monoclonal Antibodies) 8. Treatment of any type of cancer within the last 6 months except for superficial skin cancers such as basal cell carcinoma and squamous cell carcinoma. 9. History of any significant internal disease which contraindicates use of a live microbiome (e.g., leukemia, liver failure, cardiovascular disease). 10. Subjects who are known to be allergic to any of the Test article(s) or any components in the test article(s) or history of hypersensitivity or allergic reactions to any of the study preparations as described in the Investigator's Brochure. 11. AIDS or AIDS related complex by medical history. 12. History of current street drug or alcohol abuse, or street drug or alcohol abuse within the past year. 13. Known or suspected immune suppressive medications or diseases. 14. Subjects with poorly controlled diabetes mellitus Type I or II requiring medical intervention/treatment. 15. Peripheral vascular disease based on medical history. 16. Any subject not able to meet the study attendance requirements. 17. Subjects who have participated in any other trial of an investigational drug or device within 30 days prior to enrollment or participation in a research study concurrent with this study. 18. Use of any orthopedic appliance (e.g., cast, soft cast, splint) on either foot or ankle, or surgery of either foot or ankle within 90 days of the Screening visit.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
DBI-001 Gel
Topical application of DBI-001 gel on foot/feet affected with tinea pedis
DBI-002 Gel
Topical application of DBI-002 gel on foot/feet affected with tinea pedis
Aqueous Gel
Topical application of Aqueous gel on foot/feet affected with tinea pedis

Locations

Country Name City State
United States Oregon Dermatology and Research Portland Oregon
United States Premier Clinical Research Spokane Washington

Sponsors (1)

Lead Sponsor Collaborator
DermBiont, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in abundance of T. rubrum based on Quantitative Polymerase Chain Reaction (qPCR) Change in abundance of T. rubrum at baseline, day 7 and day 14 14 days of participation
Secondary Number of participants with treatment-related adverse events Safety 14 days of participation
Secondary Changes in signs and symptoms of T. Pedis Change from baseline in individual signs and symptoms of Tinea Pedis at days 7 and 14 of sites treated with DBI-001 Gel, DBI-002 Gel, or Aqueous Gel. The minimum value is 0 and the maximum value is 3 the subject's self reported observation on local tolerability. 14 days of participation
Secondary Changes in the signs and symptoms and Investigators Static Global Assessment (ISGA) of Tinea Pedis Changes from Baseline in signs and symptoms and ISGA at Days 7 and 14 14 days of participation
Secondary Change in abundance of T. rubrum based on qPCR and WGS Antimicrobial efficacy 14 days of participation
Secondary Molecular diagnostic qPCR and WGS comparison of DBI-001 Gel, DBI-002 Gel and Aqueous Gel Antimicrobial efficacy and microbiome community analysis 14 days of participation
Secondary Bacterial culture comparison of DBI-001 Gel, DBI-002 Gel and Aqueous Gel Antimicrobial efficacy and microbiome community analysis 14 days of participation
Secondary Increase or decrease of colony forming units after DBI-001 Gel, DBI-002 Gel application Antimicrobial efficacy 14 days of participation
Secondary Correlation between levels of DBI-001 Gel, DBI-002 Gel and abundance of T. rubrum based on qPCR Antimicrobial efficacy 14 days of participation
Secondary Correlation between qPCR quantification and KOH for presence of T. rubrum at screening Compare sensitivity and specificity of qPCR analysis and KOH for presence of T. rubrum at Screening 28 days from screening
See also
  Status Clinical Trial Phase
Completed NCT04883593 - A Study Comparing the Efficacy of TA103 and the Placebo Control in the Treatment of Interdigital Tinea Pedis. Early Phase 1
Terminated NCT02842021 - Efficacy and Safety of Product S2G6T-1in Patients With Symptomatic Inflammatory Interdigital Tinea Pedis Phase 2
Completed NCT01712360 - Pharmacokinetic Study of Pediatric Subjects With Tinea Cruris and Tinea Pedis Phase 4
Completed NCT00781664 - Cumulative Irritation Test Phase 1
Completed NCT03676686 - Study With Nåva Foot Cream in Patients With Tinea Pedis Interdigitalis N/A
Completed NCT01519752 - A Therapeutic Equivalence Study of Two Oxiconazole Nitrate Topical Cream Treatments for Patients With Tinea Pedis Phase 1
Completed NCT03320486 - Non-inferiority Trial of Dapaconazole Versus Ketoconazole Phase 3
Completed NCT01580891 - Evaluate the Clinical Equivalence of Two Naftifine HCl 1% Creams in Patients With Interdigital Tinea Pedis Phase 1
Completed NCT01349998 - Safety of a Topical Antifungal Treatment for Tinea Cruris, Tinea Pedis and Tinea Corporis Phase 3
Completed NCT01353976 - Safety and Efficacy of Econazole Nitrate Foam 1% in Subjects With Tinea Pedis Phase 3
Completed NCT04265521 - Study With BioCool Footcare in Subjects With Tinea Pedis Interdigitalis and Heel Cracks, Calluses and/or Dry Feet N/A
Completed NCT02633813 - BE Study of Naftifine HCL Phase 3
Recruiting NCT00856596 - Once a Day Topical Treatment for Athlete's Foot Fungus Inbetween the Toes in Males and Females Phase 3
Completed NCT00869336 - Multicenter Study of the Efficacy and Safety of Luliconazole Cream in Tinea Pedis (Athlete's Foot) Phase 2
Completed NCT00768599 - A Study of Econazole Foam 1% in Athlete's Foot Phase 2
Recruiting NCT00233493 - Spread of Dermatophytes Among Families N/A
Completed NCT03897257 - A Comparison Study of UHE-103 Cream in Subjects With Moccasin Type Tinea Pedis Phase 2
Completed NCT03129321 - Therapeutic Equivalence and Safety of Two Econazole Nitrate Cream, 1% Products in Tinea Pedis Phase 3
Completed NCT02335255 - Evaluate Safety and Efficacy of Naftifine Hydrochloride Gel 2% and Naftin® Gel 2% in Tinea Pedis Phase 1
Withdrawn NCT02606383 - Non-inferiority Phase III Trial Comparing Dapaconazole Cream 2% With Ketoconazole Cream 2% in Patients With Tinea Pedis Phase 3